620. Oral β-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance From IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis

BACKGROUND: Antibiotics can damage the gut microbiome leading to overgrowth of pathogens and provide selective pressure for emergence of antibiotic resistance. SYN-004 (ribaxamase) is a clinical-stage β-lactamase formulated for oral delivery intended to degrade certain β-lactam antibiotics in the GI...

Descripción completa

Detalles Bibliográficos
Autores principales: Connelly, Sheila, Furlan-Freguia, Christian, Fanelli, Brian, Hasan, Nur A, Colwell, Rita R, Kaleko, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254545/
http://dx.doi.org/10.1093/ofid/ofy210.627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254545/
http://dx.doi.org/10.1093/ofid/ofy210.627

Ejemplares similares